Trump and pharma execs to discuss progress on COVID-19 cure
The White House task force and the US President will meet drug makers this afternoon to discuss "progress on a vaccine and cure".
In an early morning Tweet, US President Trump said he will be meeting with major pharmaceutical companies today at the White House to discuss "progress on a vaccine and cure" for coronavirus (COVID-19) outbreak. This statement comes after the infection claimed the country's second victim during the weekend.
Although Trump provided no further information or details, including clues as to which companies would be attending, it has been reported that executives from Sanofi, Johnson & Johnson, GSK and Pfizer will be appearing at this afternoon's meeting.
The head of the infectious diseases unit at the US National Institutes of Health, Dr Anthony Fauci, said he was concerned the number of US cases could jump in the coming weeks.
“When you have a number of cases that you’ve identified and they’ve been in the community for a while, you’re going to wind up seeing a lot more cases than you would have predicted,” he told CNN in an interview on Monday. He continued to explain his concern that "we’re going to see a lot more community-related cases" during the next few weeks.
Meanwhile, on the other side of the Atlantic, Prime Minister Boris Johnson, has said the spread of coronavirus is a "problem that is likely to become more significant".
Johnson's comment comes as the number of cases in the UK rises to 40. The prime minister has also chaired a meeting today of the government's emergency committee, Cobra, to agree a plan to tackle the crisis.
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...